202 related articles for article (PubMed ID: 35939783)
1. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma.
Logue JM; Peres LC; Hashmi H; Colin-Leitzinger CM; Shrewsbury AM; Hosoya H; Gonzalez RM; Copponex C; Kottra KH; Hovanky V; Sahaf B; Patil S; Lazaryan A; Jain MD; Baluch A; Klinkova OV; Bejanyan N; Faramand RG; Elmariah H; Khimani F; Davila ML; Mishra A; Blue BJ; Grajales-Cruz AF; Castaneda Puglianini OA; Liu HD; Nishihori T; Freeman CL; Brayer JB; Shain KH; Baz RC; Locke FL; Alsina M; Sidana S; Hansen DK
Blood Adv; 2022 Dec; 6(24):6109-6119. PubMed ID: 35939783
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study.
Dima D; Rashid A; Davis JA; Shune L; Abdallah AO; Li H; DeJarnette S; Khouri J; Williams L; Hashmi H; Raza S; McGuirk J; Anwer F; Ahmed N
Br J Haematol; 2024 Apr; 204(4):1293-1299. PubMed ID: 38263627
[TBL] [Abstract][Full Text] [Related]
3. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
Anderson LD
Future Oncol; 2022 Jan; 18(3):277-289. PubMed ID: 34854741
[TBL] [Abstract][Full Text] [Related]
4. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.
Hansen DK; Sidana S; Peres LC; Colin Leitzinger C; Shune L; Shrewsbury A; Gonzalez R; Sborov DW; Wagner C; Dima D; Hashmi H; Kocoglu MH; Atrash S; Simmons G; Kalariya N; Ferreri C; Afrough A; Kansagra A; Voorhees P; Baz R; Khouri J; Alsina M; McGuirk J; Locke FL; Patel KK
J Clin Oncol; 2023 Apr; 41(11):2087-2097. PubMed ID: 36623248
[TBL] [Abstract][Full Text] [Related]
5. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi NC; Anderson LD; Shah N; Madduri D; Berdeja J; Lonial S; Raje N; Lin Y; Siegel D; Oriol A; Moreau P; Yakoub-Agha I; Delforge M; Cavo M; Einsele H; Goldschmidt H; Weisel K; Rambaldi A; Reece D; Petrocca F; Massaro M; Connarn JN; Kaiser S; Patel P; Huang L; Campbell TB; Hege K; San-Miguel J
N Engl J Med; 2021 Feb; 384(8):705-716. PubMed ID: 33626253
[TBL] [Abstract][Full Text] [Related]
6. Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial.
McGarvey N; Ung B; Carattini T; Imanak K; Lee A; Campbell TB; Patwardhan P
Adv Ther; 2023 Oct; 40(10):4626-4638. PubMed ID: 37597153
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma.
Minakata D; Ishida T; Ando K; Suzuki R; Tanaka J; Hagiwara S; Ananthakrishnan R; Kuwayama S; Nishio M; Kanda Y; Suzuki K
Int J Hematol; 2023 May; 117(5):729-737. PubMed ID: 36690910
[TBL] [Abstract][Full Text] [Related]
8. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
Rodriguez-Otero P; Ailawadhi S; Arnulf B; Patel K; Cavo M; Nooka AK; Manier S; Callander N; Costa LJ; Vij R; Bahlis NJ; Moreau P; Solomon SR; Delforge M; Berdeja J; Truppel-Hartmann A; Yang Z; Favre-Kontula L; Wu F; Piasecki J; Cook M; Giralt S
N Engl J Med; 2023 Mar; 388(11):1002-1014. PubMed ID: 36762851
[TBL] [Abstract][Full Text] [Related]
9. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study.
Caillot L; Sleiman E; Lafon I; Chretien ML; Gueneau P; Payssot A; Pedri R; Lakomy D; Bailly F; Guy J; Quenot JP; Avet-Loiseau H; Caillot D
Transplant Cell Ther; 2024 Jun; 30(6):630.e1-630.e8. PubMed ID: 38458477
[TBL] [Abstract][Full Text] [Related]
10. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.
Lee DH; Kumar A; Mohammed T; Peres LC; Alsina M; Bachmeier C; Blue BJ; Brayer J; Chandrasekhar S; Grajales Cruz A; De Avila G; Elmariah H; Faramand R; Freeman C; Jain M; Khadka S; Khimani F; Liu H; Nishihori T; Oswald LB; Castaneda Puglianini OA; Shain KH; Smith E; Baz RC; Locke FL; Oliveira GH; Alomar M; Hansen DK
Blood Adv; 2023 Aug; 7(16):4247-4257. PubMed ID: 37307173
[TBL] [Abstract][Full Text] [Related]
11. Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients.
Sanoyan DA; Seipel K; Bacher U; Kronig MN; Porret N; Wiedemann G; Daskalakis M; Pabst T
BMC Cancer; 2023 Apr; 23(1):345. PubMed ID: 37061680
[TBL] [Abstract][Full Text] [Related]
12. Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.
Delforge M; Otero PR; Shah N; Moshkovich O; Braverman J; Dhanda DS; Lanar S; Devlen J; Miera M; Gerould H; Campbell TB; Munshi NC
Leuk Res; 2023 Jun; 129():107074. PubMed ID: 37087950
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma.
Delforge M; Shah N; Miguel JSF; Braverman J; Dhanda DS; Shi L; Guo S; Yu P; Liao W; Campbell TB; Munshi NC
Blood Adv; 2022 Feb; 6(4):1309-1318. PubMed ID: 34933328
[TBL] [Abstract][Full Text] [Related]
14. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.
Sidana S; Peres LC; Hashmi H; Hosoya H; Ferreri C; Khouri J; Dima D; Atrash S; Voorhees P; Simmons G; Sborov DW; Kalariya N; Hovanky V; Bharadwaj S; Miklos D; Wagner C; Kocoglu MH; Kaur G; Davis JA; Midha S; Janakiram M; Freeman C; Alsina M; Locke F; Gonzalez R; Lin Y; McGuirk J; Afrough A; Shune L; Patel KK; Hansen DK
Haematologica; 2024 Mar; 109(3):777-786. PubMed ID: 37731379
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy.
Davis JA; Sborov DW; Wesson W; Julian K; Abdallah AO; McGuirk JP; Ahmed N; Hashmi H
Transplant Cell Ther; 2023 Sep; 29(9):567-571. PubMed ID: 37225044
[TBL] [Abstract][Full Text] [Related]
16. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T; Usmani SZ; Schecter JM; Vogel M; Jackson CC; Deraedt W; Tian H; Yeh TM; Banerjee A; Pacaud L; Garrett A; Haltner A; Cameron C; Van Sanden S; Diels J; Valluri S; Samjoo IA
Curr Med Res Opin; 2021 Oct; 37(10):1779-1788. PubMed ID: 34256668
[TBL] [Abstract][Full Text] [Related]
17. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience.
Khouri J; Dima D; Li H; Hansen D; Sidana S; Shune L; Anwer F; Sborov D; Wagner C; Kocoglu MH; Atrash S; Voorhees P; Peres L; Hovanky V; Simmons G; Williams L; Raza S; Afrough A; Anderson L; Ferreri C; Hashmi H; Davis J; McGuirk J; Goldsmith S; Borogovac A; Lin Y; Midha S; Nadeem O; Locke FL; Baz R; Hamilton B; Alsina M; Sauter C; Patel K; Kaur G
Transplant Cell Ther; 2024 Jun; ():. PubMed ID: 38834151
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France.
Karampampa K; Zhang W; Venkatachalam M; Cotte FE; Dhanda D
J Med Econ; 2023; 26(1):243-253. PubMed ID: 36705644
[TBL] [Abstract][Full Text] [Related]
19. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T; Usmani SZ; Schecter JM; Roccia T; Jackson CC; Deraedt W; Yeh TM; Banerjee A; Pacaud L; Garrett A; Bartlett M; Haltner A; Van Sanden S; Diels J; Valluri S; Samjoo IA
Curr Med Res Opin; 2023 Jan; 39(1):81-89. PubMed ID: 36271807
[TBL] [Abstract][Full Text] [Related]
20. Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial.
Shah N; Delforge M; San-Miguel J; Moshkovich O; Braverman J; Dhanda DS; Lanar S; Miera M; Williams A; Murphy R; Devlen J; Hege K; Campbell TB; Munshi NC
Leuk Res; 2022 Sep; 120():106921. PubMed ID: 35930999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
